Indeed, the proband was under idebenone therapy at the time of blood collection, and idebenone is known to activate NRF2 expression in FRDA patients (Petrillo et al., 2019; La Rosa et al., 2020a). The gene discussed is NFE2L2; the disease is Friedreich ataxia.